ARE NONPHARMACOLOGIC INTERVENTIONS FOR CHRONIC LOW BACK PAIN MORE COST EFFECTIVE THAN USUAL CARE? PROOF OF CONCEPT RESULTS FROM A MARKOV MODEL
 
   

Are Nonpharmacologic Interventions for Chronic Low Back Pain
More Cost Effective Than Usual Care? Proof of Concept
Results From a Markov Model

This section is compiled by Frank M. Painter, D.C.
Send all comments or additions to:
    Frankp@chiro.org
 
   

FROM:   Spine (Phila Pa 1976) 2019 (Oct 15); 44 (20): 1456–1464 ~ FULL TEXT

  OPEN ACCESS   


Patricia M. Herman, ND, PhD; Tara A. Lavelle, PhD; Melony E. Sorbero, PhD;
Eric L. Hurwitz, DC, PhD; Ian D. Coulter, PhD

RAND Corporation,
Santa Monica, CA.



Study design:   Markov model.

Objective:   Examine the 1-year effectiveness and cost-effectiveness (societal and payer perspectives) of adding nonpharmacologic interventions for chronic low back pain (CLBP) to usual care using a decision analytic model-based approach.

Summary of background data   : Treatment guidelines now recommend many safe and effective nonpharmacologic interventions for CLBP. However, little is known regarding their effectiveness in subpopulations (e.g., high-impact chronic pain patients), nor about their cost-effectiveness.

Methods:   The model included four health states: high-impact chronic pain (substantial activity limitations); no pain; and two others without activity limitations, but with higher (moderate-impact) or lower (low-impact) pain. We estimated intervention-specific transition probabilities for these health states using individual patient-level data from 10 large randomized trials covering 17 nonpharmacologic therapies. The model was run for nine 6-week cycles to approximate a 1-year time horizon. Quality-adjusted life-year weights were based on six-dimensional health state short form scores; healthcare costs were based on 2003 to 2015 Medical Expenditure Panel Survey data; and lost productivity costs used in the societal perspective were based on reported absenteeism. Results were generated for two target populations: (1) a typical baseline mix of patients with CLBP (25% low-impact, 35% moderate-impact, and 40% high-impact chronic pain) and (2) high-impact chronic pain patients.

Results:   From the societal perspective, all but two of the therapies were cost effective (<$50,000/quality-adjusted life-year) for a typical patient mix and most were cost saving. From the payer perspective fewer were cost saving, but the same number was cost-effective. Assuming all patients in the model have high-impact chronic pain increases the effectiveness and cost-effectiveness of most, but not all, therapies indicating that substantial benefits are possible in this subpopulation.

There is more like this @ our:

LOW BACK PAIN Section and the:

COST-EFFECTIVENESS Section and the:

NON-PHARMACOLOGIC THERAPY Section

Conclusion:   Modeling leverages the evidence produced from clinical trials to provide more information than is available in the published studies. We recommend modeling for all existing studies of nonpharmacologic interventions for CLBP.

Level of evidence:   4.



From the FULL TEXT Article:

Introduction

Many safe and effective nonpharmacologic interventions for chronic low back pain (CLBP) are recommended in treatment guidelines. [1–4] Recommended interventions include therapies such as acupuncture, mindfulness-based stress reduction, and yoga. Although these nonpharmacologic therapies have been available to the public for years, many are not part of the healthcare system, prescribed by physicians, nor generally covered by third-party payer plans. In addition, although all recommended therapies are effective, it is unknown whether some are more effective than others, especially for certain patient groups, and their impact on costs.

The effectiveness of each recommended nonpharmacologic therapy is supported by systematic reviews and meta-analyses over dozens of studies. [3, 5–7] In a few cases, these studies directly compare two or more of the recommended therapies, but usually each therapy is studied as adjunct to usual care and compared to usual care alone. Network meta-analysis (NMA, aka multiple or mixed treatment comparisons) is one technique that goes beyond traditional pairwise meta-analysis to allow comparisons and ranking between therapies that were not directly compared in clinical trials. [8–11] However, the application of this technique requires that each therapy be directly compared to at least one comparator also used in another trial, thus, allowing indirect comparisons. Because of its common use, the logical common comparator for most therapies is usual care. However, the substantial variation across studies in what constitutes usual care and the lack of other common comparators lowers the reliability of NMA results. [8]

Decision analytic modeling is another method to synthesize evidence and compare across therapies. [12, 13] Modeling allows consistent inputs to be used across interventions, the simulation of experiments such as head-to-head trials, and the inclusion of economic outcomes even when they were not included in the original studies. [12, 14]

Since each therapy is studied as an addition to usual care, its likely incremental effects in other healthcare settings can be estimated by comparing to the version of usual care used in the trial.

The 2016 US National Pain Strategy (NPS) [15] placed a focus on those with high-impact chronic pain defined as that “associated with substantial restriction of participation in work, social, and self-care activities for six months or more.” [15], p11 Studies have used different algorithms to identify those with high-impact chronic pain, [16–21] and to demonstrate their significantly higher healthcare costs, lower quality of life, worse mood, and increased absenteeism. [18–27] Nevertheless, studies of interventions for chronic pain still report results based on full samples — e.g., average change in symptoms or percent of patients who improve. To better understand chronic pain, better compare study results, and better target interventions, we need to move beyond simple duration of pain definitions (e.g., 3+ months) to identify meaningful chronic pain subtypes. Modeling can then be used to balance the baseline subtype mix of patients across studies and estimate differential treatment effects by subtype (e.g., chronic pain impact level).

Although several economic evaluations of nonpharmacologic therapies for CLBP have been published, [28–34] because economic outcomes are not generalizable across settings, [35] each study’s results can only provide useful information about cost impacts in its country and setting. Modeling is used to adjust inputs and assumptions to adapt study results to other settings. [36]

This study presents the results of a proof-of-concept modeling effort that utilized individual patient-level data from ten randomized studies and the categorization of these study’s participants by chronic pain impact level to estimate the effectiveness and cost-effectiveness of adding recommended nonpharmacologic therapies for CLBP to usual care.



Methods

This study used a Markov simulation model to compare the effectiveness and cost-effectiveness of a set of recommended nonpharmacologic therapies for CLBP. This modeling effort was part of a larger study examining the appropriateness of spinal mobilization and manipulation (M/M) for CLBP. [37, 38] This model was built to provide information to expert panels on the cost-effectiveness of M/M as compared to other nonsurgical interventions for CLBP to see if this information would change their original safety and effectiveness-based ratings of the appropriateness of M/M. To ensure face and construct validity [39] and maximize the model’s usefulness and relevance, [40] we built it with the input of two experts in the use of M/M for CLBP (ELH and HV) and a nine-member panel of expert representatives of the types of policy makers who could use the model’s results.

Figure 1

The model included transition probabilities that moved a hypothetical cohort of patients between four defined health states every 6 weeks for just over a year (Figure 1). One health state was defined as high-impact chronic pain (individuals with substantial activity limitations); [15] one as a healthy, no pain state; and two others were without activity limitations, but with higher (moderate-impact) or lower (low-impact) pain. We estimated intervention-specific transition probabilities for these health states using individual patient-level data from the 10 trials [41–50] covering 17 nonpharmacologic therapies. Trials of M/M and other common nonpharmacologic interventions for CLBP were chosen following these inclusion criteria: large sample sizes (e.g., at least 50 per arm), all (or most) of the subjects experienced CLBP (≥3 months’ duration), at least 6 months follow up, and US-, Canada- or UK-based for ease of acquisition and similar usual care. We also required that the study measured variables that were useful for the estimation of chronic pain impact levels—i.e., measures of pain, function and quality of life. Four trial datasets [41–43, 48] contained direct measure of chronic pain impact level using the Graded Chronic Pain Scale (GCPS): [20, 25, 27, 51, 52] low-impact (Grade I), moderate-impact (Grade II), and high-impact (Grade III/IV) chronic pain. Chronic pain impact levels were estimated for the other datasets using logistic models with excellent predictive power [53] using patients’ pain intensity, Roland-Morris Disability scores, [51, 54] and SF-1255 or SF-3656 items as independent variables. Details on the datasets acquired and the identification of each patient’s health state at baseline and over time are provided elsewhere. [53]

Table 1

Each health state was assigned a quality of life or quality-adjusted life-year (QALY) weight (calculated as the SF-6D [57, 58] score over 6 weeks) and 6-week costs (Table 1). The healthcare costs were estimated from 2003–2015 Medical Expenditure Panel Survey (MEPS, http://meps.ahrq.gov/mepsweb/) data, [59] and represent average US-based 2015 healthcare costs associated with back pain. Estimates of absenteeism and utility were taken from trial data as described elsewhere. [53] Productivity loss was estimated based on patient-reported absenteeism for those employed, and valued using the human capital approach [60] at the US Bureau of Labor Statistics June 2015 national average employer cost of employee compensation for civilian workers of $33.19. [61] The simulation tracked a cohort of hypothetical new CLBP patients over nine 6-week cycles and summed QALY gains and costs to yield estimated 54-week health and cost outcomes.

The resources used in the delivery of the nonpharmacologic interventions and usual care were captured from the information available in each study’s publications. The unit costs for each type of practitioner used were estimated as the average (after trimming the top and bottom 5%) of the costs per visit available in the MEPS. The full list of unit costs and their sources, the information available from each study, and the resulting treatment costs for each therapy are shown in Appendix.



Analysis

For each therapy, the model projected progression across health states based on estimated transition probabilities — i.e., the likelihood that an individual receiving that intervention will stay in their present state or move to another health state for the next 6-week cycle. Transition probabilities were estimated based on actual patient progression through health states in trial data. Nine trials measured outcomes over one year and the other50 went out 6 months. This study’s 6-month outcomes were held constant to 12 months based on the 6–12-month results of another yoga study. [62]

Because each study’s data collection occurred at different intervals, each study’s empirical transition probability matrix was first converted into a weekly matrix by translating the empirical probabilities into weekly rates and then converted into 6-week cycles that could be used in the model. We defined a typical mix of CLBP patients as having the following proportions at baseline: 25% low-impact, 35% moderate-impact, and 40% high-impact chronic pain. These proportions reflect the average baseline mix of patients in the trials used in the model. [53]

The Markov model was run for nine 6-week cycles to approximate a 1-year (54 week) time horizon. As individuals cycled through the health states they accumulated healthcare costs, productivity loss, and QALYs according to the values in Table 1. The model is probabilistic in that the effect of the uncertainty (SEs) of the mean input parameters, and of our estimation of the transition probabilities, was reflected in measures of output uncertainty (e.g., confidence intervals around 1-year costs and QALY gains). [63] Because each intervention was studied as adjunct to usual care, incremental costs and effects for each therapy were calculated net of each study’s version of usual care. The model allows estimation of relative effectiveness and cost-effectiveness across all therapies. However, because these therapies are not equally available and accessible, [64] and may not be equally acceptable to patients, our main results are presented for each therapy compared to usual care, and comparisons across all therapies are presented in the Appendix. Two studies did not include a usual care arm. [48, 65] For each we assigned two US-based usual care options based on the need for similar data collection schedules (see Appendix for details).

Finally, we performed tests of internal consistency (do model input changes have predictable effects on outputs) and external consistency (comparing model results to that shown in published studies). [40] The Markov models were run using TreeAge Pro 2018 R2.1, Williamstown, MA, and other analyses used Microsoft Excel 2016, Redmond, WA.



Results

Table 2

Table 3

Figure 2

Table 2 gives the model’s incremental results compared to usual care for the societal and payer perspectives for a typical mix of chronic low-back pain patients. Table 3 shows the same information assuming all patients start with high-impact chronic pain. Figure 2 graphically displays the incremental point estimates for a typical mix of patients from the societal perspective. The 0,$0 point represents usual care and points below $50,000/QALY (a commonly defined threshold66) are generally considered cost-effective. As can be seen, all interventions but two (Traditional Chinese acupuncture and spinal manipulation assuming the same usual care) are cost-effective, many therapies have similar effectiveness and cost-effectiveness, and most showed cost savings from the societal perspective. The distance between the two versions of each intervention with assigned usual care arms indicates the sensitivity of interventions’ impacts to underlying usual care.

Yoga had the largest effects and cost savings. In fact, in terms of relative cost-effectiveness yoga was dominant — i.e., had lower costs and higher QALY gains than any other intervention (see Appendix). When costs are included from the payer perspective the same interventions are cost-effective, but fewer are cost saving.

When we assume all patients start with high-impact chronic pain, the results are more favorable for many therapies. However, some therapies have less favorable results: cognitive: cognitive behavioral therapy (CBT) educational program, chiropractic care, exercise, multidisciplinary care, and Traditional Chinese medicine (TCM) acupuncture, all had smaller QALY gains and higher costs in the high-impact group than with a typical mix of patients.

All internal consistency checks were successful. Model outputs responded as expected to variations in intervention costs, other healthcare costs, utilities, and transition probabilities. The Appendix contains the results of two tests of external consistency. Even though complete consistency is not expected since the model balanced baseline patient mixes and estimated QALYs, the model’s ranking of within-study functional effectiveness across arms was identical to that seen in the published studies. We also saw a consistent relationship between difference-in-difference estimates of function and incremental QALYs across studies.



Discussion

We present the results of a Markov model that estimates the effectiveness and cost-effectiveness of adding 17 nonpharmacologic interventions for CLBP to usual care. This model provides information beyond what is available from the individual studies, systematic reviews, and meta-analyses. The model estimates comparable results across studies by balancing baseline patient mixes (as would be expected with randomization), and using similar outcome measures (e.g., QALYs based on SF-6D, productivity costs and healthcare costs). Also, because we had patient-level data and were able to categorize patients into chronic pain impact levels to better track outcomes, and we were able to examine the effectiveness and cost-effectiveness of interventions assuming all patients start with one level of chronic pain. These results are useful to the better design and targeting of nonpharmacologic interventions for CLBP, and the use of a common set of US-based cost inputs provides US policy makers with initial estimates of economic impacts.

Our model’s health states were defined by chronic pain impact levels, and the results targeting high-impact chronic pain indicate that the biggest effects and costs for most interventions occur in these activity-limited patients. Given the number of other studies showing worse outcomes for patients with high-impact chronic pain—e.g., significantly higher healthcare costs, lower quality of life, worse mood, and more absenteeism18–27—it is not surprising that these patients would have a different response to treatment. However, this is the first study that examines how their response varies.

As with any Markov model, transition probabilities drive outcomes. Our transition probabilities were calculated from individual trial participants’ transitions through the health states they experienced over the trial year. Healthcare costs are related to patients’ health states, but health outcomes directly determine health states. Therefore, more confidence should be placed in the model’s estimates of QALY gains than of costs. One US cost-effectiveness analysis alongside a randomized trial of mindfulness-based stress reduction (MBSR) and group CBT for CLBP did find QALY gains in the range shown in model results. [31] It also found that MBSR was cost saving from the societal and payer perspectives, and that CBT was cost neutral from the societal and likely cost-effective ($24,000/QALY) from the payer perspective, therefore, our cost estimates are reasonable. Nevertheless, modeling cost results should be interpreted with caution, considered more for their relative than absolute values, and replicated in relevant settings.

Another recent Markov model used three health states (chronic pain, improved pain, and death) to examine the relative effectiveness and cost-effectiveness of cognitive and mind-body therapies for CLBP. [67, 68] That model used 6-month cycles over 5 years, defined improved pain as ≥30% improvement in the RMDQ, and used other estimates for QALYs and healthcare costs as inputs. They concluded that yoga and MBSR offered high value for the money given their effectiveness and cost-effectiveness, acupuncture and CBT for pain offered intermediate value, and all four had evidence adequate to support coverage.

While we believe this model is useful, it is not without limitations. It now includes the results for 10 large randomized trials and 17 nonpharmacologic interventions for CLBP. Many other studies have been done that could be added to increase the information available, and the added studies might include therapies that are not as effective. This model in its present state should be considered a demonstration of how the results of different studies can be compared, and its results should not be used to make decisions. With more examples of each intervention, we could also examine the effect of any differences in protocols across studies. It is possible to use calibration to estimate transition probabilities from published studies when patient-level data are not available. However, confidence in these calibrated results would be lower. We used one measure of chronic pain impact levels to define our health states. There could be other health state definitions or other measures of chronic pain impact that would be more appropriate and better track effects and costs. To obtain estimates of the incremental effects for 3 interventions, we assigned usual care arms from those available from the other studies. We don’t know how close the assigned usual care arms are to the actual usual care underlying those studies, but the range in outcomes generated across the options assigned demonstrates the importance of including a usual care arm if a trial’s results are to be generalizable.

Markov modeling of nonpharmacologic interventions for CLBP is feasible and provides useful information about the effectiveness and cost-effectiveness of these interventions relative to usual care. According to model assumptions these interventions all improve health-related quality of life (QALYs) over usual care, and most, significantly so. In addition, most of these interventions appear cost-effective (and even cost saving) from the payer and societal perspectives, and many of the interventions have their largest impacts on those with high-impact chronic pain. Modeling leverages the investment made in existing trials to provide more useful information than is available from the published studies. We recommend this modeling effort be expanded to include data from all existing studies of nonpharmacologic interventions for chronic low back pain.


Supplementary Material

Supplemental Data File (175K, docx)


Contributor Information

Patricia M Herman, RAND Corporation, Santa Monica, CA.

Tara A Lavelle, Center for the Evaluation of Value and Risk in Health, Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, and RAND Corporation, Boston, MA.

Melony E Sorbero, RAND Corporation, Pittsburgh, PA.

Eric L Hurwitz, Office of Public Health Studies, University of Hawaii, Manoa, Honolulu, HI.

Ian D Coulter, RAND Corporation, Santa Monica, CA.


Acknowledgments:

The authors gratefully acknowledge all members of the extensive team that made this work possible including Nicholas Broten, Prodyumna Goutam, John Luke Irwin, Nima Shahidinia, and Howard Vernon. The authors would also like to acknowledge the following individuals and institutions who generously shared their data for this study: Dr. Jerilyn Cambron; Dr. Ram Gudavalli; Dr. Mitch Haas at the University of Western States; Dr. Eric Hurwitz; Drs. Daniel Cherkin, James E. Moore, Karen Sherman, and Michael Von Korff of Kaiser Permanente Washington Research Institute (formerly Group Health Research Institute); and the University of Warwick. Finally, the authors would like to thank the nine members of the panel of expert policy maker representatives, including Larry Becker, Rupali Das, Charles R Elder, R Lloyd Friesen, Christine M Goertz, and Anthony J Lisi.

The National Center for Complementary and Integrative Health (NICCIH) of the National Institutes of Health (NIH) (award number 1U19AT007912–01) funds were received in support of this work.

Relevant financial activities outside the submitted work: grants.


References:

  1. Qaseem A, Wilt TJ, McLean RM, Forciea MA;
    Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain:
    A Clinical Practice Guideline From the American College of Physicians

    Annals of Internal Medicine 2017 (Apr 4); 166 (7): 514–530

  2. The Diagnosis and Treatment of Low Back Pain Work Group.
    VA/DoD Clinical Practice Guideline for Diagnosis and Treatment of Low Back Pain
    Washington, DC: The Office of Quality, Safety and Value, VA, &
    Office of Evidence Based Practice, U.S. Army MedicalCommand, 2017, Version 2.0.

  3. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, et al.
    Nonpharmacologic Therapies for Low Back Pain: A Systematic Review
    for an American College of Physicians Clinical Practice Guideline

    Annals of Internal Medicine 2017 (Apr 4); 166 (7): 493–505

  4. The Joint Commission.
    Non-pharmacologic and non-opioid solutions for pain management.
    Quick Safety. 2018;August(44):1–2.

  5. Skelly AC, Chou R, Dettori JR, Turner JA, Friedly JL, et al.
    Noninvasive Nonpharmacological Treatment for Chronic Pain:
    A Systematic Review Update

    Comparative Effectiveness Review Number 227
    Rockville (MD): Agency for Healthcare Research and Quality (2020)

  6. Childs JD, Cleland JA, Elliott JM, et al.
    Neck pain: clinical practice guidelines linked to the International
    Classification of Functioning, Disability, and Health from the Orthopaedic
    Section of the American Physical Therapy Association.
    J Orthop Sports Phys Ther. 2008;38(9):A1–A34.

  7. Chou RMD, Atlas SJMDMPH, Stanos SPDO, Rosenquist RWMD.
    Nonsurgical Interventional Therapies for Low Back Pain: A Review
    of the Evidence for an American Pain Society Clinical Practice Guideline.
    Spine. 2009;34(10):1066–1077,1078–1093.

  8. Tonin FS, Rotta I, Mendes AM, Pontarolo R.
    Network meta-analysis: a technique to gather evidence from direct and indirect comparisons.
    Pharmacy Practice (Granada). 2017;15(1).

  9. Li T, Puhan MA, Vedula SS, Singh S, Dickersin K.
    Network meta-analysis-highly attractive but more methodological research is needed.
    BMC Med. 2011;9(1):79.

  10. Jansen JP, Naci H.
    Is network meta-analysis as valid as standard pairwise meta-analysis?
    It all depends on the distribution of effect modifiers. B
    MC Med. 2013;11(1):159.

  11. Mills EJ, Thorlund K, Ioannidis JP.
    Demystifying trial networks and network meta-analysis.
    BMJ. 2013;346:f2914.

  12. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S.
    Good practice guidelines for decision-analytic modelling
    in health technology assessment.
    PharmacoEcon. 2006;24(4):355–371.

  13. Briggs AH, Goeree R, Blackhouse G, O’Brien BJ.
    Probabilistic analysis of cost-effectiveness models:
    choosing between treatment strategies for gastroesophageal reflux disease.
    Med Decis Making. 2002;22(4):290–308.

  14. Buxton MJ, Drummond MF, Van Hout BA, et al.
    Modelling in ecomomic evaluation: an unavoidable fact of life.
    Health Econ. 1997;6(3):217–227.

  15. Office of the Assistant Secretary for Health.
    National Pain Strategy: A Comprehensive Population
    Health-Level Strategy for Pain

    Washington, DC: US Department of Health and Human Services,
    National Institutes of Health; 2016.

  16. Dahlhamer J, Lucas J, Zelaya C, et –al.
    Prevalence of Chronic Pain and High-Impact Chronic Pain
    Among Adults - United States, 2016

    MMWR Morb Mortal Wkly Rep. 2018 (Sep 14); 67 (36): 1001-1006

  17. R.A. Deyo, S.F. Dworkin, D. Amtmann, G. Andersson, et al.,
    Report of the NIH Task Force on Research Standards for Chronic Low Back Pain
    Journal of Pain 2014 (Jun); 15 (6): 569–585

  18. Nahin RL.
    Estimates of pain prevalence and severity in adults: United States, 2012.
    J Pain. 2015;16(8):769–780.

  19. Pitcher MH, Von Korff M, Bushnell MC, Porter L.
    Prevalence and Profile of High-Impact Chronic Pain in the United States.
    J Pain. 2018.

  20. Von Korff M, Ormel J, Keefe FJ, Dworkin SF.
    Grading the severity of chronic pain.
    Pain. 1992;50(2):133–149.

  21. Von Korff M, Scher AI, Helmick C, et al.
    United States National Pain Strategy for Population Research:
    Concepts, Definitions, and Pilot Data.
    J Pain. 2016;17(10):1068–1080.

  22. Davis MA.
    Where the United States Spends its Spine Dollars: Expenditures on Different
    Ambulatory Services for the Management of Back and Neck Conditions

    Spine (Phila Pa 1976). 2012 (Sep 1); 37 (19): 1693–1701

  23. Engel CC, Von Korff M, Katon WJ.
    Back pain in primary care: predictors of high health-care costs.
    Pain. 1996;65(2–3):197–204.

  24. Gaskin DJ, Richard P.
    The economic costs of pain in the United States.
    J Pain. 2012;13(8):715–724.

  25. Smith BH, Penny KI, Purves AM, et al.
    The Chronic Pain Grade questionnaire: validation and reliability in postal research.
    Pain. 1997;71(2):141–147.

  26. Taylor-Stokes G, Lobosco S, Pike J, Sadosky AB, Ross E.
    Relationship between patient-reported chronic low back pain severity and medication resources.
    Clin Ther. 2011;33(11):1739–1748.

  27. Von Korff M.
    Assessment of Chronic Pain in Epidemiological and Health Services Research:
    Empirical Bases and New Directions
    In: Turk DC, Melzack R, eds. Handbook of Pain Assessment.
    Third Edition ed. New York:
    Guilford Press; 2011:455–473.

  28. Herman PM, Poindexter BL, Witt CM, Eisenberg DM.
    Are complementary therapies and integrative care cost-effective?
    A systematic review of economic evaluations.
    BMJ Open. 2012;2(5):e001046.

  29. Chuang L-H, Soares MO, Tilbrook H, et al.
    A pragmatic multicentered randomized controlled trial of yoga for
    chronic low back pain: economic evaluation.
    Spine. 2012;37(18):1593–1601.

  30. Vavrek DA, Sharma R, Haas M.
    Cost Analysis Related to Dose-response of Spinal Manipulative Therapy for
    Chronic Low Back Pain: Outcomes from a Randomized Controlled Trial

    J Manipulative Physiol Ther. 2014 (Jun); 37 (5): 300–311

  31. Herman PM, Anderson ML, Sherman KJ, Balderson BH, Turner JA, Cherkin DC.
    Cost-effectiveness of mindfulness-based stress reduction versus cognitive
    behavioral therapy or usual care among adults with chronic low back pain.
    Spine. 2017;42(20):1511–1520.

  32. Herman PM, Szczurko O, Cooley K, Mills EJ.
    Cost-effectiveness of naturopathic care for chronic low back pain.
    Altern Ther Health Med. 2008;14(2).

  33. Lamb SE, Hansen Z, Lall R, et al.
    Group cognitive behavioural treatment for low-back pain in primary care:
    a randomised controlled trial and cost-effectiveness analysis.
    The Lancet. 2010;375(9718):916–923.

  34. Aboagye E, Karlsson ML, Hagberg J, Jensen I.
    Cost-effectiveness of early interventions for non-specific low back pain:
    a randomized controlled study investigating medical yoga, exercise therapy and self-care advice.
    J Rehabil Med. 2015;47(2):167–173.

  35. Drummond M, Manca A, Sculpher M.
    Increasing the generalizability of economic evaluations: recommendations
    for the design, analysis, and reporting of studies.
    Int J Technol Assess Health Care. 2005;21(2):165–171.

  36. Drummond M, M. B, Cook J, et al.
    Transferability of economic evaluations across jurisdictions:
    ISPOR good research practices task force report.
    Value Health. 2009;12(4):409–418.

  37. Coulter ID, Herman PM, Ryan GW, Hays RD, Hilton LG, Whitley MD.
    Researching the Appropriateness of Care in the Complementary
    and Integrative Health Professions: Part I

    J Manipulative Physiol Ther. 2018 (Nov); 41 (9): 800–806

  38. Coulter ID, Herman PM, Ryan GW, Hays RD, Hilton LJ, CERC Team.
    The Challenge of Determining Appropriate Care in the Era of
    Patient-Centered Care and Rising Health Care Costs.
    J Health Serv Res Policy. 2018;[in press].

  39. Trochim WMK.
    The Research Methods Knowledge Base, Second Edition.
    Cincinnati, OH: Atomic Dog Publishing; 2001.

  40. Phillips Z, Bojke L, Sculpher M, Claxton K, Golder S.
    Good practice guidelines for decision-analytic modelling in health
    technology assessment: a review and consolidation of quality assessment.
    Pharmacoeconomics. 2006;24(4):355–371.

  41. Moore JE, Von Korff M, Cherkin D, Saunders K, Lorig K.
    A randomized trial of a cognitive-behavioral program for enhancing
    back pain self care in a primary care setting.
    Pain. 2000;88(2):145–153.

  42. Underwood M, UK BEAM Trial Team.
    United Kingdom Back Pain Exercise and Manipulation (UK BEAM) Randomised Trial:
    Effectiveness of Physical Treatments for Back Pain in Primary Care

    British Medical Journal 2004 (Dec 11); 329 (7479): 1377–1384

  43. Von Korff M, Balderson BH, Saunders K, et al.
    A trial of an activating intervention for chronic back pain in
    primary care and physical therapy settings.
    Pain. 2005;113(3):323–330.

  44. Cambron JA, Gudavalli MR, Hedeker D, et al.
    One-year follow-up of a randomized clinical trial comparing
    flexion distraction with an exercise program for
    chronic low-back pain.
    J Altern Complement Med. 2006;12(7):659–668.

  45. Cherkin DC, Eisenberg D, Sherman KJ, et al.
    Randomized trial comparing traditional Chinese medical acupuncture,
    therapeutic massage, and self-care education for chronic low back pain.
    Arch Intern Med. 2001;161(8):1081–1088.

  46. Cherkin DC, Sherman KJ, Avins AL, et al.
    A randomized trial comparing acupuncture, simulated acupuncture, and
    usual care for chronic low back pain.
    Arch Intern Med. 2009;169(9):858–866.

  47. Cherkin DC, Sherman KJ, Kahn J, et al.
    A comparison of the effects of 2 types of massage and usual care on
    chronic low back pain: a randomized, controlled trial.
    Ann Intern Med. 2011;155(1):1–9.

  48. Haas M, Vavrek D, Peterson D, Polissar N, Neradilek MB.
    Dose-response and Efficacy of Spinal Manipulation for Care of Chronic Low Back Pain:
    A Randomized Controlled Trial

    Spine J. 2014 (Jul 1); 14 (7): 1106–1116

  49. Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F, Adams AH
    A Randomized Trial of Medical Care with and without Physical Therapy and Chiropractic Care
    with and without Physical Modalities for Patients with Low Back Pain:
    6-month Follow-up Outcomes From the UCLA Low Back Pain Study

    Spine (Phila Pa 1976) 2002 (Oct 15); 27 (20): 2193–2204

  50. Sherman KJ, Cherkin DC, Erro J, Miglioretti DL, Deyo RA.
    Comparing yoga, exercise, and a self-care book for chronic low back pain:
    a randomized, controlled trial.
    Ann Intern Med. 2005;143(12):849–856.

  51. Underwood MR, Barnett AG, Vickers MR.
    Evaluation of Two Time-Specific Back Pain Outcome Measures.
    Spine. 1999;24(11):1104–1112.

  52. Penny KI, Purves AM, Smith BH, Chambers WA, Smith WC.
    Relationship between the chronic pain grade and measures of physical,
    social and psychological well-being.
    Pain. 1999;79(2):275–279.

  53. Herman PM, Broten N, Lavelle TA, Sorbero ME, Coulter ID.
    Exploring the Prevalence and Characteristics of High-Impact Chronic Pain
    Across Chronic Low-Back Pain Study Samples.
    Spine Journal. 2019;[in press].

  54. Roland M, Morris R.
    A study of the natural history of back pain: part I: development of a
    reliable and sensitive measure of disability in low-back pain.
    Spine. 1983;8(2):141–144.

  55. Ware JE Jr, Kosinski M, Keller SD.
    A 12-item short-form health survey: construction of scales
    and preliminary tests of reliability and validity.
    Med Care. 1996;34(3):220–233.

  56. Ware JE Jr, Sherbourne CD.
    The MOS 36-item short-form health survey (SF-36): I.
    Conceptual framework and item selection.
    Med Care. 1992:473–483.

  57. Brazier J, Roberts J, Deverill M.
    The estimation of a preference-based measure of health from the SF-36.
    J Health Econ. 2002;21(2):271–292.

  58. Brazier J, Rowen D, Hanmer J.
    Revised SF-6D scoring programmes: a summary of improvements.
    PRO Newsletter. 2008;40:14–15.

  59. Herman PM, Broten N, Lavelle TA, Sorbero ME, Coulter ID.
    Healthcare Costs and Opioid Use Associated with High-Impact
    Chronic Spinal Pain in the United States.
    Spine. 2019;[in press].

  60. van den Hout WB.
    The value of productivity: human-capital versus friction-cost method.
    Ann Rheum Dis. 2010;69((Suppl 1)):i89–i91.

  61. Bureau of Labor Statistics.
    Employer Costs for Employee Compensation -
    Historical Listing March 2004 – June 2018

    US Department of Labor. National Compensation Survey

  62. Tilbrook HE, Cox H, Hewitt CE, et al.
    Yoga for chronic low back pain: a randomized trial.
    Ann Intern Med. 2011;155(9):569–578.

  63. Briggs A, Sculpher M, Claxton K.
    Decision modelling for health economic evaluation.
    OUP Catalogue. 2006.

  64. Heyward J, Jones CM, Compton WM, et al.
    Coverage of Nonpharmacologic Treatments for Low Back Pain
    Among US Public and Private Insurers

    JAMA Network Open 2018 (Oct 5); 1 (6): e183044

  65. Cambron JA, Gudavalli MR, McGregor M, et al.
    Amount of health care and self-care following a randomized clinical trial
    comparing flexion-distraction with exercise program for chronic low back pain.
    Chiropr Osteopat. 2006;14(24):19.

  66. Neumann PJ, Cohen JT, Weinstein MC.
    Updating cost-effectiveness—the curious resilience of
    the $50,000-per-QALY threshold.
    New Engl J Med. 2014;371(9):796–797.

  67. Tice JA, Kumar V, Otuonye I, et al.
    Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain:
    Effectiveness and Value: Final Evidence Report.
    Boston, MA: Institute for Clinical and Economic Review;2017.

  68. Cherkin DC, Herman PM.
    Cognitive and Mind-Body Therapies for Chronic Low Back Pain and Neck Pain:
    Effectiveness and Value.
    JAMA Internal Medicine. 2018;178(4):556–557

Return to LOW BACK PAIN

Return to COST-EFFECTIVENESS

Return NON-PHARMACOLOGIC THERAPY

Since 12-26-2021

                       © 1995–2022 ~ The Chiropractic Resource Organization ~ All Rights Reserved